

August 31, 2017



Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD

Live video webcast on Tuesday, September 5th at 12:00 PM ET

NORWOOD, MA -- (Marketwired) -- 08/31/17 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will host a live video webcast (details below) on Tuesday, September 5, 2017 at 12:00 PM ET to discuss [dermatomyositis](#): the disease, its treatment, and its impact on patients' lives.

[Barbara White, MD Chief Medical Officer, Corbus Pharmaceuticals, Inc.](#), will moderate a fireside chat with Victoria Werth, MD, Chief, Dermatology, Philadelphia V.A. Hospital, Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, Professor of Medicine, University of Pennsylvania, a key opinion leader in dermatomyositis who has authored over 150 related peer-reviewed papers. Additionally, an individual living with dermatomyositis will take part in the conversation.

Corbus is currently evaluating its lead product candidate, [anabasum](#), in an on-going Phase 2 study for the treatment of dermatomyositis. Enrollment was completed in May 2017 and Corbus is on track to report topline data from the Phase 2 study early in the fourth quarter of 2017. In November 2016, the Company [commenced a one-year, open-label extension](#) to provide subjects in the Phase 2 study with the option of continuing anabasum treatment beyond their completion of the 16-week, double-blind placebo controlled portion of the study.

The single-center, Phase 2 study in skin-predominant dermatomyositis is being conducted at the University of Pennsylvania School of Medicine and is funded by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health ("NIH"). For more information on the Phase 2 study with anabasum for the treatment of skin-predominant dermatomyositis, please visit [ClinicalTrials.gov](#) and reference Identifier NCT02466243.

Webcast Details

Interested parties may access a live video [webcast](#) and accompanying slide presentation on the [Events](#) page of the [Investors](#) section of the Company's website at

www.CorbusPharma.com. The webcast will be accessible for 90 days following the event.

About Anabasum

Anabasum is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and human clinical studies have shown anabasum to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have direct effects on fibroblasts to halt tissue scarring. In effect, anabasum triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive results in two Phase 2 studies, one in diffuse cutaneous systemic sclerosis and one in cystic fibrosis. Additionally, anabasum is being evaluated in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis, and soon in another Phase 2 study in systemic lupus erythematosus.

Corbus plans to commence a Phase 3 study of anabasum for the treatment of systemic sclerosis in the fourth quarter of 2017. The Company is also planning to initiate a larger and longer Phase 2b study of anabasum for the treatment of cystic fibrosis by the end of the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on [Twitter](#), [LinkedIn](#), [Google+](#) and [Facebook](#).

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,"

"predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: (908) 938-1475
Email: [Email contact](#)

Media Contact

Nic DiBella
JPA Health Communications
Phone: (617) 657-1307
Email: [Email contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.